Cyclic GMP protein kinase mediates negative metabolic and functional effects of cyclic GMP in control and hypertrophied rabbit cardiac myocytes

Journal of Cardiovascular Pharmacology

Volumn 34, Issue 2, 1999, Pages 229-236

  Straznicka, Michaela ^a   Gong, Gary ^a   Yan, Lin ^a   Scholz, Peter M ^a   Weiss, Harvey R ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Cardiac myocyte cyclic GMP; Myocyte O2 consumption; Myocyte shortening; Renal hypertension

Indexed keywords

CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; KT 5823; PROTEIN KINASE INHIBITOR; ZAPRINAST;

ANIMAL CELL; ARTICLE; CELL METABOLISM; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RABBIT; RENOVASCULAR HYPERTENSION; SECOND MESSENGER;

ALKALOIDS; ANIMALS; CARBAZOLES; CARDIOMEGALY; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; INDOLES; MYOCARDIUM; OXYGEN CONSUMPTION; PURINONES; RABBITS;

EID: 0032797658     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199908000-00008     Document Type: Article

References (30)

1. Lohmann SM, Fischmeister R, Walter U. Signal transduction by cGMP in heart. Basic Res Cardiol 1991;86:503-14.
2. Murad F. The nitric oxide-cyclic GMP signal transduction system for intracellular and extracellular communication. Recent Prog Horm Res 1994;49:239-48.
3. 2+ in intact cardiac myocytes. Circ Res 1994;74:970-8.
4. Sperelakis N, Tohse N, Ohya Y, Masuda H. Cyclic GMP regulation of calcium slow channels in cardiac muscle and vascular smooth muscle cells. Adv Pharmacol 1994;26:217-52.
5. Lincoln TM, Cornwell T. Intracellular cyclic GMP receptor proteins. FASEB J 1993;7:328-38.
6. Koyda G, Kottenberg K, Nix P, Schluter KD, Piper HM, Noack E. Low increase in cGMP induced by organic nitrates and nitrovasodilators improves contractile response of rat ventricular myocytes. Circ Res 1996;78:91-101.
7. 2+ channel activity by human natriuretic peptide in rabbit heart cells. Br J Pharmacol 1995;114:1076-82.
8. 2+ current is regulated by cyclic GMP-dependent protein kinase in mammalian cardiac myocytes. Proc Natl Acad Sci USA 1991;88:1197-201.
9. Wahler GM, Dollinger SJ. Nitric oxide donor SIN-1 inhibits mammalian cardiac calcium current through cGMP-dependent protein kinase. Am J Physiol 1995;268:C45-54.
10. de Jonge HR. Cyclic GMP-dependent protein kinase in intestinal brush borders. Adv Cyclic Nucleotide Res 1981;14:315-33.
11. Lincoln TM, Keely SL. Regulation of cardiac cGMP-dependent protein kinase. Biochim Biophys Acta 1980;676:230-44.
12. Nichols JR, Gonzalez NC. Increase in myocardial cell cGMP concentration in pressure-induced myocardial hypertrophy. J Mol Cell Cardiol 1982;14:181-218.
13. Roitstein A, Kedem J, Cheinberg B, Weiss JR, Tse J, Scholz PM. The effect of intracoronary nitroprusside on cyclic GMP and regional mechanics is altered in a canine model of left ventricular hypertrophy. J Surg Res 1994;57:584-90.
14. 2 consumption is altered in renal hypertension. Am J Physiol 1997;273:H1949-55.
15. 4-induced cardiac hypertrophy. Am J Physiol 1995;268:686-91.
16. Rabindranauth P, Naim KL, Scholz PM, Tse J, Sadoff JD, Weiss HR. Negative metabolic effects of cGMP are altered in renal hypertension induced cardiac hypertrophy. Basic Res Cardiol 1997; 92:8-16.
17. Kuo F, Davis CW, Tse J. Depressed cardiac cyclic GMP-dependent protein kinase in spontaneously hypertensive rats and its further depression by guanethidine. Nature 1976;261:335-6.
18. Ecker T, Gobel C, Hullin R, Rettig R, Seitz G, Hofmann F. Decreased cardiac concentration of cGMP kinase in hypertensive animals. Circ Res 1989;65:1361-9.
19. 2 supply and consumption in early cardiac hypertrophy of renal hypertensive rabbits. Basic Res Cardiol 1989;84:13-21.
20. Gong G, Weiss HR, Tse J, Scholz PM. Exogenous nitric oxide reduces oxygen consumption of isolated ventricular myocytes less than other forms of guanylate cyclase stimulation. Eur J Pharmacol 1998;344:299-305.
21. Kase H, Iwahashi K, Nakanishi S, et al. K-252 compounds: novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases. Biochem Biophys Res Commun 1987; 142:436-40.
22. Butt E, Eigenthaler M, Genieser H-G. (Rp)-8-pCPT-cGMPs: a novel cGMP-dependent kinase inhibitor. Eur J Pharmacol 1994; 269:265-8.
23. Burt JM, Spray DC. Inotropic agents modulate gap junctional conductance between cardiac myocytes. Am J Physiol 1988;254: H1206-10.
24. Lincoln TM, Corbin JD. Characterization and biological role of the cGMP-dependent protein kinase. Adv Cyclic Nucleotide Res 1983; 15:139-92.
25. Gong X, Weiss HR, Tse J, Scholz PM. Cyclic GMP decreases cardiac myocyte oxygen consumption to a greater extent under conditions of increased metabolism. J Cardiovasc Pharmacol 1997;30:537-43.
26. Nawrath H, Baumner D, Rupp J, Oelert H. The ineffectiveness of the NO-cyclic GMP signaling pathway in the atrial myocardium. Br J Pharmacol 1995;116:3061-7.
27. Joyce NC, Decamilli P, Lohmann SM, Walter U. cGMP-dependent protein kinase is present in high concentrations in contractile cells of the kidney vasculature. J Cyclic Nucleotide Protein Phosphor Res 1986;11:191-8.
28. Waldmann R, Bauer S, Gobel C, Hofmann F, Jakobs KH, Walter U. Demonstration of cGMP-dependent phosphorylation in cell-free extracts of platelets. Eur J Biochem 1986;158:203-10.
29. Jakob G, Mair J, Pichler M, Puschendorf B. Ergometric exercise testing and sensitivity of cyclic guanosine 3′,5′-monophosphate (cGMP) in diagnosing asymptomatic left ventricular dysfunction. Br Heart J 1995;73:145-50.
30. Dowell RT, Haithcoat JL, Thirkill HM, Palmer WK. Heart cyclic nucleotide responses to sustained aortic constriction in neonatal and adult rat. Am J Physiol 1984;246:H197-206.